Brokerages expect Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) to announce earnings of ($0.16) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Cyclacel Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.17) and the highest estimate coming in at ($0.14). Cyclacel Pharmaceuticals reported earnings of ($0.18) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 11.1%. The business is expected to report its next quarterly earnings results on Monday, November 11th.
According to Zacks, analysts expect that Cyclacel Pharmaceuticals will report full year earnings of ($0.63) per share for the current year, with EPS estimates ranging from ($0.68) to ($0.57). For the next fiscal year, analysts expect that the business will post earnings of ($0.59) per share, with EPS estimates ranging from ($0.59) to ($0.58). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Cyclacel Pharmaceuticals.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.01).
Several brokerages recently weighed in on CYCC. Zacks Investment Research cut Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 16th. HC Wainwright reaffirmed a “buy” rating on shares of Cyclacel Pharmaceuticals in a research note on Wednesday, May 15th. Finally, Roth Capital reiterated a “buy” rating on shares of Cyclacel Pharmaceuticals in a research report on Thursday, May 23rd. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $5.00.
A hedge fund recently raised its stake in Cyclacel Pharmaceuticals stock. Renaissance Technologies LLC lifted its stake in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 82.5% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,102,400 shares of the biotechnology company’s stock after purchasing an additional 498,200 shares during the quarter. Renaissance Technologies LLC owned 6.41% of Cyclacel Pharmaceuticals worth $596,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 5.36% of the company’s stock.
CYCC stock traded down $0.01 during trading hours on Thursday, hitting $0.46. 4,574 shares of the stock traded hands, compared to its average volume of 71,286. The firm has a 50-day moving average of $0.56. Cyclacel Pharmaceuticals has a one year low of $0.28 and a one year high of $1.87. The firm has a market capitalization of $8.66 million, a P/E ratio of -0.74 and a beta of 2.98. The company has a current ratio of 8.09, a quick ratio of 8.09 and a debt-to-equity ratio of 0.08.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.
Featured Story: Price-Sales Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.